PriceTargets.com logo

NASDAQ:SLS - SELLAS Life Sciences Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.38
  • Forecasted Upside: 102.59 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$9.07 As of 10/20/2021 01:00 AM ET
▲ +0.09 (1.00%)

This chart shows the closing price for SLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SELLAS Life Sciences Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLS

Analyst Price Target is $18.38
▲ +102.59% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for SELLAS Life Sciences Group in the last 3 months. The average price target is $18.38, with a high forecast of $21.00 and a low forecast of $16.50. The average price target represents a 102.59% upside from the last price of $9.07.

This chart shows the closing price for SLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in SELLAS Life Sciences Group.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2021Cantor FitzgeraldInitiated CoverageOverweight$18.00High
6/25/2021Maxim GroupBoost Price TargetPositive ➝ Buy$12.00 ➝ $21.00Medium
6/21/2021Royal Bank of CanadaInitiated CoverageOutperform$18.00Low
6/3/2021Alliance Global PartnersBoost Price TargetBuy$8.00 ➝ $16.50Medium
5/14/2021Maxim GroupReiterated RatingBuy$12.00N/A
2/27/2020Maxim GroupReiterated RatingBuy$12.00N/A
11/15/2019Maxim GroupUpgradeHold ➝ BuyN/A
4/8/2019Alliance Global PartnersInitiated CoverageBuy$225.00N/A
3/22/2019Maxim GroupDowngradeBuy ➝ HoldN/A
12/6/2018Maxim GroupSet Price TargetBuy$250.00N/A
11/26/2018Maxim GroupSet Price TargetBuy$250.00N/A
11/15/2018OppenheimerSet Price TargetBuy$650.00N/A
11/15/2018Maxim GroupSet Price TargetBuy$250.00N/A
11/1/2018CIBCInitiated CoverageOutperform ➝ OutperformN/A
11/1/2018OppenheimerInitiated CoverageOutperform$650.00N/A
10/22/2018Maxim GroupReiterated RatingBuy$250.00N/A
7/31/2018HC WainwrightSet Price TargetBuy$200.00N/A
7/20/2018Maxim GroupLower Price TargetBuy ➝ Buy$650.00 ➝ $250.00N/A
6/5/2018HC WainwrightSet Price TargetBuy$550.00N/A
6/1/2018Maxim GroupReiterated RatingBuy$650.00N/A
4/16/2018Maxim GroupSet Price TargetBuy$650.00N/A
4/16/2018HC WainwrightSet Price TargetBuy$550.00N/A
4/2/2018HC WainwrightReiterated RatingBuy$11.00High
4/2/2018Maxim GroupSet Price TargetBuy$650.00N/A
4/2/2018HC WainwrightInitiated CoverageBuy ➝ Buy$550.00N/A
3/19/2018Maxim GroupUpgradeHold ➝ Buy$650.00N/A
12/18/2017Raymond JamesReiterated RatingHoldLow
8/9/2017Maxim GroupReiterated RatingHoldHigh
2/6/2017FBR & Co.DowngradeOutperform ➝ Market Perform$550.00 ➝ $200.00N/A
2/2/2017Maxim GroupDowngradeBuy ➝ HoldN/A
1/5/2017FBR & Co.Reiterated RatingOutperform$550.00N/A
1/3/2017Maxim GroupReiterated RatingBuy$200.00N/A
12/4/2016FBR & Co.Reiterated RatingOutperform$550.00N/A
12/2/2016Maxim GroupBoost Price TargetBuy$50.00 ➝ $200.00N/A
11/11/2016Maxim GroupReiterated RatingBuy$50.00N/A
10/23/2016Maxim GroupReiterated RatingBuy$50.00N/A
(Data available from 10/21/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2021

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

SELLAS Life Sciences Group logo
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. It engages in the development and commercialization of immunotherapeutic for cancer indications. The firm's product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
Read More

Today's Range

Now: $9.07
Low: $8.89
High: $9.18

50 Day Range

MA: $9.37
Low: $8.21
High: $10.53

52 Week Range

Now: $9.07
Low: $2.33
High: $19.38

Volume

98,473 shs

Average Volume

858,616 shs

Market Capitalization

$143.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of SELLAS Life Sciences Group?

The following sell-side analysts have issued research reports on SELLAS Life Sciences Group in the last year: Alliance Global Partners, Cantor Fitzgerald, Maxim Group, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for SLS.

What is the current price target for SELLAS Life Sciences Group?

4 Wall Street analysts have set twelve-month price targets for SELLAS Life Sciences Group in the last year. Their average twelve-month price target is $18.38, suggesting a possible upside of 101.9%. Maxim Group has the highest price target set, predicting SLS will reach $21.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $16.50 for SELLAS Life Sciences Group in the next year.
View the latest price targets for SLS.

What is the current consensus analyst rating for SELLAS Life Sciences Group?

SELLAS Life Sciences Group currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLS will outperform the market and that investors should add to their positions of SELLAS Life Sciences Group.
View the latest ratings for SLS.

What other companies compete with SELLAS Life Sciences Group?

Other companies that are similar to SELLAS Life Sciences Group include Inventiva, Intercept Pharmaceuticals, Albireo Pharma, Rigel Pharmaceuticals, Nkarta, Seres Therapeutics, Rhythm Pharmaceuticals, Spero Therapeutics, SIGA Technologies, Adagene, Clovis Oncology, Summit Therapeutics, Basilea Pharmaceutica, Akebia Therapeutics and Zomedica.

How do I contact SELLAS Life Sciences Group's investor relations team?

SELLAS Life Sciences Group's physical mailing address is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. The company's listed phone number is (646) 200-5278 and its investor relations email address is [email protected] The official website for SELLAS Life Sciences Group is www.sellaslifesciences.com.